Condition (MeSH)
Tuberculosis, Pulmonary
ClinicalTrials.gov lists 308 trials for Tuberculosis, Pulmonary or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 15.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
308 of the 308 trials are tagged with Tuberculosis, Pulmonary itself; the rest are tagged with a narrower condition beneath it.
When did Tuberculosis, Pulmonary trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 31
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 19 |
| 2025 | 16 |
| 2024 | 16 |
| 2023 | 19 |
| 2022 | 31 |
| 2021 | 26 |
| 2020 | 16 |
| 2019 | 21 |
| 2018 | 15 |
| 2017 | 20 |
Showing 10 of 27 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 23 trials starting in 2026 and about 18 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 33 months from start to primary completion across 32 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 173 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tuberculosis, Pulmonary trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 23 |
| Phase 1/2 | 6 |
| Phase 2 | 73 |
| Phase 2/3 | 11 |
| Phase 3 | 35 |
| Phase 4 | 15 |
| Not applicable | 60 |
| Observational | 85 |
How many Tuberculosis, Pulmonary trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 18 |
| Recruiting | 35 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 8 |
| Completed | 170 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Tuberculosis, Pulmonary trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 15 |
| Centers for Disease Control and Prevention | 4 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 |
Which drugs are being tested for Tuberculosis, Pulmonary? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Bedaquiline | 30 |
| Delamanid | 14 |
| Clofazimine | 12 |
| BTZ-043 | 6 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Rifampicin | 34 |
| Pyrazinamide Oral Product | 31 |
| Isoniazida | 29 |
| Ethambutol Oral Product | 25 |
| C: moxifloxacin | 23 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Tuberculosis, Pulmonary trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Haemoptysis | 30 | 9 |
| Electrocardiogram QT prolonged | 25 | 2 |
| Dyspnoea | 19 | 4 |
| Pneumothorax | 18 | 10 |
| Anaemia | 16 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Tuberculosis, Pulmonary? (889)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial. | The Lancet. Infectious diseases | 2026 | Yes |
| Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya. | BMJ open | 2026 | Yes |
| Truenat MTB assays for pulmonary tuberculosis and rifampicin resistance in adults and adolescents. | The Cochrane database of systematic reviews | 2025 | Yes |
| Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial. | The Lancet. Infectious diseases | 2025 | Yes |
| N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis. | The Journal of infection | 2025 | Yes |
Showing 5 of 889 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Primary pulmonary tuberculosis | 645814 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Primary pulmonary tuberculosis | 645814 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.